Claims~~WHAT IS CLAIMED IS:~~

1. A method for adapting an influenza virus to Vero cells, comprising:

-(i) infecting Vero cells with an influenza virus at a first infectious dose;

-(ii) cultivating infected Vero cells in a spinner flask to produce ~~viral activities~~an influenza virus culture;

-(iii) harvesting the influenza virus from said ~~a first~~ influenza virus culture;

-(iv) ~~infecting Vero cells with~~passaging ~~said first~~ influenza virus from (iii) in Vero cells at a ~~second~~ subsequent infectious dose to produce a subsequent~~econd~~ influenza virus culture~~viral activities~~, wherein said ~~second~~subsequent infectious dose is greater than or equal to ~~said first~~the previous infectious dose;

~~-harvesting a second influenza virus; and~~

-repeating ~~the process~~(iii) to (v), and harvesting a Vero cell adapted culture of influenza virus~~.~~

~~2. A method of claim 1~~, wherein at least one of said first infectious dose and said ~~second~~subsequent infectious dose is expressed by MOI, and the MOI is 0,00001, 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 1.5, 2.0, or any value between 0.00001 and 2.0 and the number of passages ranges from 5 to 10.

~~3~~2. A method of claim 1~~ or 2~~, wherein at least one of said first infectious dose and said second infectious dose is expressed by MOI, and the MOI of influenza virus is 0.00001, 0.00004, 0.00013, 0.0002, 0.0011, 0.0013, 0.002 0.0022, 0.0026, 0.0072, 0.008, 0.018, 0.019, 0.030, 0.033, 0.05, 0.16, 0.22, 0.25, 0.47, 0.5, 0.63,

1.0, 1.58, 1.6, or 2.0.

43. A method of claim 32, wherein said first infectious dose is 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of said second infectious dose.

54. A method of claim 1 or 2, wherein saideach viral cell culture produces viral activitiesy compriseing viral replication, viral production, hemagglutinin (HA) titer or neuraminidase (NA) titer.

~~6. A method of claim 1 or 2, further comprising passing an influenza virus in the Vero cells with a number of passages of 5-10.~~

75. A method of any one of claims 1 to 64, wherein said number of passages is 5, 6, 7, 8, 9, or 10.

86. A method of claim 75, wherein said influenza virus is acquired from embryonated chicken eggs, allantoic cavity of chicken embryo, or amniotic membrane of chicken embryo.

97. A method of claim 86, wherein said influenza virus is selected from a group including A/California/7/2009(H1N1)pdm09, A/Michigan/45/2015(H1N1)pdm09, A/Switzerland/9715293/2013(H3N2), A/Hong Kong/4801/2014(H3N2), B/Brisbane/60/2008, and B/Phuket/3073/2013.

108. A method of claim 86, comprising using said Vero cell adapted influenza viruses to produce a composition, wherein said composition comprises polyriboinosinic acid-polyribocytidylic acid (PIC), at least one antibiotic or polyamide compound, at least one positive ion, influenza viruses and/or influenza antigens.

~~11~~9. A method of claim ~~10~~8, wherein at least one of said influenza antigens is selected from a group including HA and NA; wherein said polyamide compound is selected from a group including spermidine sault, spermidine, N-(3-aminopropyl), N-(3-aminopropyl)-1,4-butandiamine, spermine BR, spermine, OS-dimethylphosphoramidothioate, polylysine, and aminoglycoside; and wherein said positive ion is selected from a group including calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, and zinc.

1~~2~~0. A method of claim ~~10~~8 or ~~11~~9, wherein said composition is formulated for ~~comprising~~ administrationg ~~said composition~~ by nasal spray, intramuscular delivery, intravenous delivery, and/or oral administration.

1~~3~~1. A method of any one of claims 1 to 12, comprising cultivating the Vero cells in a single-use bioreactor.